Induction of acquired immunity in rats that have eliminated intracranial gliosarcoma cells by the expression of herpes simplex virus thymidine kinase gene and ganciclovir administration

Oncology (Switzerland)

Volumn 54, Issue 4, 1997, Pages 329-334

  Iwadate, Yasuo ^a   Namba, Hiroki ^b   Tagawa, Masatoshi ^a   Takenaga, Keizo ^b   Sueyoshi, Kanji ^b   Sakiyama, Shigeru ^b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Antitumor immunity; Glioblastoma; Herpes simplex virus thymidine kinase; Major histocompatibility complex

Indexed keywords

GANCICLOVIR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; THYMIDINE KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLONE; GENETIC TRANSDUCTION; GLIOSARCOMA; HERPES SIMPLEX VIRUS; HISTOLOGY; INTRACRANIAL TUMOR; LYMPHOCYTIC INFILTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, NEOPLASM; BRAIN NEOPLASMS; CELL DIVISION; GANCICLOVIR; GLIOSARCOMA; HISTOCOMPATIBILITY ANTIGENS CLASS I; RATS; RATS, INBRED F344; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0030965978     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227712     Document Type: Article

References (20)

1. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, Mac-Carty CS, Mahalcy MS Jr, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323-1329.
2. Oldfield EH: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993:4:39-69.
3. Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J, Karkas JC, Ashton WT, Johnston DBR, Tolman RL: 9-{[2-Hy-droxy-1 -(hydroxymethyl)cthoxy]mcthyl} guanine: A selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 1983:80: 4139-4143.
4. Teppcr RI, Mule JJ: Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994:5:153-164.
5. Baker CF, Billingham RE: Immunologically privileged sites. Adv Immunol 1977;25:1-54.
6. Aarli JA: The immune system and nervous system. J Neurol 1983;229:137-154.
7. Jacobs SK, Melin G, Holcomb B, Parham CW, Komblith PL, Grimm EA: Lymphokinc activated killer (LAK) cell-mediated lysis of murine glioma: Trypsin-chymolrypsin-scnsitive glioma protein is responsible for tumor-selective recognition by LAK cells. Brain Res 1986:372:386-389.
8. Holladay FP, Lopez G, Dc M, Morantz RA, Wood GW: Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary' in vitro stimulation with tumor cells. Neurosurgery' 1992:30:499-505.
9. Yamasaki T, Klein G, Ljunggren H-G, Karrc K, Moritake K, Paine JT, Kikuchi H: Role of histocompatibility antigen gene and proto-on-cogenc expressions in intracerebral tumorige-nicity of mouse neuroblastoma. J Neurosurg 1993;78:619-629.
10. Lampson LA, Lampson MA, Dunne AD: Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: Use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ. Cancer Res 1993;53: 176-182.
11. Cignetti A, Guarini A, Carbone A, Fomi M, Cronin K, Fomi G, Gansbacher B, Foa R: T ransduction of the IL2 gene into human acute leukemia cells: Induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J Natl Cancer Inst 1994; 86:785-791.
12. Ljunggren H-G, Yamasaki T, Collins P, Klein G, Karre K: Selective acceptance of MHC class I-dcficient tumor grafts in the brain. J Exp Med 1988;167:730-735.
13. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D: Regulation of established macroscopic liver mctastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993;90:7024-7028.
14. Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudinc M, Spence AM: Gene therapy of rat 9L gliosarcoma tumors by transduction with selective genes does not require drug selection. Proc Natl Acad Sci USA 1994;91:8185-8189.
15. Peters PJ, Necfjcs JJ, Oorschot V, Ploegh HL, Geuze HJ: Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature 1991;349:669-676.
16. Wallich R, Bulbue N, Hämmerling GJ, Katzav S, Segal S, Feldman M: Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigen following H-2 gene transfection. Nature 1985;315:301-305.
17. Hui KM, Sim T, Foo TT, Oei A-A: Tumor rejection mediated by transfection with allogenic class I histocompatibility gene. J Immunol 1989;143:3835-3843.
18. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E: Retroviral vector-mediated gamma-intcrferon gene transfer into tu-morcclls generates potent and long lasting antitumor immunity. Cancer Res 1990:50:7820-7825.
19. Fcaron ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vo-gelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
20. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH, Gansbacher B: Retroviral vector-mediated lymphokinc gene transfer into human renal cancer cells. Cancer Res 1992:52: 6229-6236.